You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search

Lipodystrophy
Fat Loss / Fat Accumulation / Wasting / Cosmetic Procedures / Growth Hormone / Buffalo Hump

Tesamorelin (Egrifta) Now Available to Manage HIV-related Lipodystrophy
1-28-2011

FDA Approves Tesamorelin (Egrifta) for Management of Lipodystrophy in People with HIV
11-12-2010

FDA Committee Unanimously Votes to Approve Tesamorelin (Egrifta) for Lipodystrophy
6-4-2010

Growth Hormone Releasing Factor Tesamorelin Reduces Visceral Fat in HIV Positive People with Lipodystrophy
4-2-2010

Medicare Will Now Cover Facial Fillers for HIV Positive People Experiencing Depression Due to Lipoatrophy

3-26-2010

Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 Randomized Trial : Results at 48 weeks

3-1-2010

ACTG 5202 Sub-study Finds Lipoatrophy Uncommon, Antiretroviral Drugs Have Varying Effects on Bone and Body Fat
3-1-2010

Body Composition and Metabolic Changes in the SMART Treatment Interruption Trial
2-16-2010

Successful Treatment of Facial Lipoatrophy with a New Formulation of Hyaluronic Acid (Restylane SubQ)

10-20-2009

Switching from Lopinavir/ritonavir (Kaletra) to Boosted Atazanavir (Reyataz) Reduces Visceral Fat and Improves Glucose Metabolism
7-10-2009


4-Year Study Finds Polyacrylamine Hydrogel (Aquamid) Facial Filler Is a Safe and Satisfactory Treatment for Lipoatrophy
5/05/09

Durable Effects of Polylactic Acid for Facial Lipoatrophy in People with HIV

4/10/09


Inflammatory Blood Vessel Activation Is Enhanced in HIV Positive People Independent of Antiretroviral Therapy and Lipoatrophy
12/05/2008

Strength Training Improves Insulin Sensitivity and Reduces Body Fat in HIV Positive Patients with Lipodystrophy
10/17/08


Long-term Safety and Effectiveness of Growth Hormone Releasing Factor Tesamorelin for Lipodystrophy
9/15/08

Genetic Factors May Influence Fat Loss and Accumulation in People with HIV

9/15/08

Switching from Other Ritonavir-boosted Protease Inhibitors to Boosted Atazanavir (Reyataz) Did Not Improve Body Fat Accumulation: REAL Study
8/19/2008


Growth Hormone Improves Lipodystrophy, but Has Detrimental Effect on Blood Glucose
8/08/08


Abdominal Fat Accumulation, Elevated ALT, and Liver Steatosis in HIV Positive Individuals
6/24/08


Phse 3 Study Shows Growth Hormone Releasing Factor Tesamorelin Reduces Excess Visceral Fat in HIV patients
6/20/08


Long-term Fat Loss among Treatment-naive Patients Starting Combination Therapy Containing Stavudine (Zerit), Zidovudine (Retrovir), or Abacavir (Ziagen)
5/30/08

Body Fat and Blood Lipid Levels in Men and Women with HIV
5/16/08

Genetic Variation Predicts Higher Risk of Lipoatrophy in Patients on HAART
5/02/08


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
  
Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors EIs
Integrase Inhibitors

Experimental Treatments

HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children